
Home » OTC Naloxone Nasal Spray Gains Priority Review
OTC Naloxone Nasal Spray Gains Priority Review
The FDA has accepted Harm Reduction Therapeutics’ (HRT) new drug application (NDA) for RiVive, an investigational over-the-counter (OTC) nasal spray containing 3 mg of naloxone, and has granted the compound a priority review.
The combination drug-device, which is intended as an emergency treatment for accidental opioid overdose, has the potential to widely expand the availability of naloxone.
The NDA is supported by phase 1 data demonstrating that RiVive produces a three-fold higher systemic exposure with comparable early absorption to the reference naloxone product.
HRT has entered into a commercial supply agreement with a contract manufacturer in anticipation of FDA approval and U.S. launch in early 2024.
The agency is expected to make an approval decision by April 28, 2023.
Upcoming Events
-
28Sep
-
28Sep
-
11Oct
-
16Oct
-
26Oct
-
08Nov